Pharmacologic properties of (-)-3PPP (preclamol) in man

C. A. Tamminga, N. G. Cascella, R. A. Lahti, M. Lindberg, A. Carlsson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar "rising dose" placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalJournal of Neural Transmission
Volume88
Issue number3
DOIs
StatePublished - Oct 1992

Fingerprint

Pharmaceutical Preparations
Placebos
Safety
Antipsychotic Agents
Growth Hormone
Pharmacokinetics
Autoreceptors
preclamol
Dopamine Agonists
Half-Life
Volunteers
Schizophrenia
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • (-)-3PPP
  • antipsychotic
  • autoreceptor
  • Partial dopamine agonist
  • schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Tamminga, C. A., Cascella, N. G., Lahti, R. A., Lindberg, M., & Carlsson, A. (1992). Pharmacologic properties of (-)-3PPP (preclamol) in man. Journal of Neural Transmission, 88(3), 165-175. https://doi.org/10.1007/BF01244730

Pharmacologic properties of (-)-3PPP (preclamol) in man. / Tamminga, C. A.; Cascella, N. G.; Lahti, R. A.; Lindberg, M.; Carlsson, A.

In: Journal of Neural Transmission, Vol. 88, No. 3, 10.1992, p. 165-175.

Research output: Contribution to journalArticle

Tamminga, CA, Cascella, NG, Lahti, RA, Lindberg, M & Carlsson, A 1992, 'Pharmacologic properties of (-)-3PPP (preclamol) in man', Journal of Neural Transmission, vol. 88, no. 3, pp. 165-175. https://doi.org/10.1007/BF01244730
Tamminga, C. A. ; Cascella, N. G. ; Lahti, R. A. ; Lindberg, M. ; Carlsson, A. / Pharmacologic properties of (-)-3PPP (preclamol) in man. In: Journal of Neural Transmission. 1992 ; Vol. 88, No. 3. pp. 165-175.
@article{f05e471c3de14c058ecef1a6f6ba9214,
title = "Pharmacologic properties of (-)-3PPP (preclamol) in man",
abstract = "The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar {"}rising dose{"} placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.",
keywords = "(-)-3PPP, antipsychotic, autoreceptor, Partial dopamine agonist, schizophrenia",
author = "Tamminga, {C. A.} and Cascella, {N. G.} and Lahti, {R. A.} and M. Lindberg and A. Carlsson",
year = "1992",
month = "10",
doi = "10.1007/BF01244730",
language = "English (US)",
volume = "88",
pages = "165--175",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pharmacologic properties of (-)-3PPP (preclamol) in man

AU - Tamminga, C. A.

AU - Cascella, N. G.

AU - Lahti, R. A.

AU - Lindberg, M.

AU - Carlsson, A.

PY - 1992/10

Y1 - 1992/10

N2 - The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar "rising dose" placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.

AB - The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar "rising dose" placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.

KW - (-)-3PPP

KW - antipsychotic

KW - autoreceptor

KW - Partial dopamine agonist

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0026632497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026632497&partnerID=8YFLogxK

U2 - 10.1007/BF01244730

DO - 10.1007/BF01244730

M3 - Article

C2 - 1358119

AN - SCOPUS:0026632497

VL - 88

SP - 165

EP - 175

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 3

ER -